Use of intravitreal bevacizumab or triamcinolone acetonide as a preoperative adjunct to vitrectomy for vitreous haemorrhage in diabetics

Detalhes bibliográficos
Autor(a) principal: Ferraz,Daniel Araújo
Data de Publicação: 2013
Outros Autores: Morita,Celso, Preti,Rony Carlos, Nascimento,Vinicius Paganini, Maia Junior,Otacílio Oliveira, Barros,André Carvalho de, Takahashi,Beatriz Sayuri, Takahashi,Walter Yukihiko
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Revista Brasileira de Oftalmologia (Online)
Texto Completo: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0034-72802013000100003
Resumo: PURPOSE: To evaluate the effect of preoperative intravitreal bevacizumab (IVB) or triamcinolone (IVT) on the rate of early postvitrectomy hemorrhage in proliferative diabetic retinopathy (PDR). METHODS: Eligible eyes were assigned randomly to 1 of 3 groups: the IVB group received 1.25 mg bevacizumab, the IVT group received 4,0mg triamcinolone and the control group underwent a sham procedure. The primary outcome measure was the incidence of early postvitrectomy hemorrhage. Secondary outcome measures included changes in visual acuity (BCVA) and adverse events. RESULTS: Twenty and seven eyes, 9 in each group were randomized. The incidence of vitreous hemorrhage was lower in the IVB group (p=0.18). Postoperative vitreous hemorrhage at 1 month also was less in the IVB group compared with the control group (p &gt; 0.05). The rate of bleeding immediately after surgery was higher in IVT group with 4 (44.4%) cases. The overall mean visual acuity was 1.72 ± 0.37 logMAR preoperatively and 1.32 ± 0.73 logMAR in 6 months after surgery. Accessing visual acuity by group evidenced that the IVB group had initial mean logMAR VA of 1.87 and 1.57 logMAR VA at the six months (p = 0.84). In IVT group, initial mean VA was 1.75 logMAR and 0.96 logMAR VA at six months (p < 0.001). And in control group, the initial mean VA was 1.85 logMAR and 1.57 logMAR VA at six months (p= 0.34). CONCLUSION: Intravitreal injection of bevacizumab 1 week before vitrectomy seems to reduce the incidence of early postvitrectomy hemorrhage in diabetic patients. There was a better visual acuity outcome in the triamcinolone group.
id SBO-1_8d88e4fbaa793dc17cf3f06c7517ff0d
oai_identifier_str oai:scielo:S0034-72802013000100003
network_acronym_str SBO-1
network_name_str Revista Brasileira de Oftalmologia (Online)
repository_id_str
spelling Use of intravitreal bevacizumab or triamcinolone acetonide as a preoperative adjunct to vitrectomy for vitreous haemorrhage in diabeticsDiabetic retinopathy/surgeryVitrectomyAngiogenesis inhibitors/therapeutic useTriamcinolone/therapeutic useVisual acuityPURPOSE: To evaluate the effect of preoperative intravitreal bevacizumab (IVB) or triamcinolone (IVT) on the rate of early postvitrectomy hemorrhage in proliferative diabetic retinopathy (PDR). METHODS: Eligible eyes were assigned randomly to 1 of 3 groups: the IVB group received 1.25 mg bevacizumab, the IVT group received 4,0mg triamcinolone and the control group underwent a sham procedure. The primary outcome measure was the incidence of early postvitrectomy hemorrhage. Secondary outcome measures included changes in visual acuity (BCVA) and adverse events. RESULTS: Twenty and seven eyes, 9 in each group were randomized. The incidence of vitreous hemorrhage was lower in the IVB group (p=0.18). Postoperative vitreous hemorrhage at 1 month also was less in the IVB group compared with the control group (p &gt; 0.05). The rate of bleeding immediately after surgery was higher in IVT group with 4 (44.4%) cases. The overall mean visual acuity was 1.72 ± 0.37 logMAR preoperatively and 1.32 ± 0.73 logMAR in 6 months after surgery. Accessing visual acuity by group evidenced that the IVB group had initial mean logMAR VA of 1.87 and 1.57 logMAR VA at the six months (p = 0.84). In IVT group, initial mean VA was 1.75 logMAR and 0.96 logMAR VA at six months (p < 0.001). And in control group, the initial mean VA was 1.85 logMAR and 1.57 logMAR VA at six months (p= 0.34). CONCLUSION: Intravitreal injection of bevacizumab 1 week before vitrectomy seems to reduce the incidence of early postvitrectomy hemorrhage in diabetic patients. There was a better visual acuity outcome in the triamcinolone group.Sociedade Brasileira de Oftalmologia2013-02-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S0034-72802013000100003Revista Brasileira de Oftalmologia v.72 n.1 2013reponame:Revista Brasileira de Oftalmologia (Online)instname:Sociedade Brasileira de Oftalmologia (SBO)instacron:SBO10.1590/S0034-72802013000100003info:eu-repo/semantics/openAccessFerraz,Daniel AraújoMorita,CelsoPreti,Rony CarlosNascimento,Vinicius PaganiniMaia Junior,Otacílio OliveiraBarros,André Carvalho deTakahashi,Beatriz SayuriTakahashi,Walter Yukihikoeng2013-03-05T00:00:00Zoai:scielo:S0034-72802013000100003Revistahttps://rbo.emnuvens.com.br/rbo/indexhttps://old.scielo.br/oai/scielo-oai.phpsob@sboportal.org.br||rbo@sboportal.org.br1982-85510034-7280opendoar:2013-03-05T00:00Revista Brasileira de Oftalmologia (Online) - Sociedade Brasileira de Oftalmologia (SBO)false
dc.title.none.fl_str_mv Use of intravitreal bevacizumab or triamcinolone acetonide as a preoperative adjunct to vitrectomy for vitreous haemorrhage in diabetics
title Use of intravitreal bevacizumab or triamcinolone acetonide as a preoperative adjunct to vitrectomy for vitreous haemorrhage in diabetics
spellingShingle Use of intravitreal bevacizumab or triamcinolone acetonide as a preoperative adjunct to vitrectomy for vitreous haemorrhage in diabetics
Ferraz,Daniel Araújo
Diabetic retinopathy/surgery
Vitrectomy
Angiogenesis inhibitors/therapeutic use
Triamcinolone/therapeutic use
Visual acuity
title_short Use of intravitreal bevacizumab or triamcinolone acetonide as a preoperative adjunct to vitrectomy for vitreous haemorrhage in diabetics
title_full Use of intravitreal bevacizumab or triamcinolone acetonide as a preoperative adjunct to vitrectomy for vitreous haemorrhage in diabetics
title_fullStr Use of intravitreal bevacizumab or triamcinolone acetonide as a preoperative adjunct to vitrectomy for vitreous haemorrhage in diabetics
title_full_unstemmed Use of intravitreal bevacizumab or triamcinolone acetonide as a preoperative adjunct to vitrectomy for vitreous haemorrhage in diabetics
title_sort Use of intravitreal bevacizumab or triamcinolone acetonide as a preoperative adjunct to vitrectomy for vitreous haemorrhage in diabetics
author Ferraz,Daniel Araújo
author_facet Ferraz,Daniel Araújo
Morita,Celso
Preti,Rony Carlos
Nascimento,Vinicius Paganini
Maia Junior,Otacílio Oliveira
Barros,André Carvalho de
Takahashi,Beatriz Sayuri
Takahashi,Walter Yukihiko
author_role author
author2 Morita,Celso
Preti,Rony Carlos
Nascimento,Vinicius Paganini
Maia Junior,Otacílio Oliveira
Barros,André Carvalho de
Takahashi,Beatriz Sayuri
Takahashi,Walter Yukihiko
author2_role author
author
author
author
author
author
author
dc.contributor.author.fl_str_mv Ferraz,Daniel Araújo
Morita,Celso
Preti,Rony Carlos
Nascimento,Vinicius Paganini
Maia Junior,Otacílio Oliveira
Barros,André Carvalho de
Takahashi,Beatriz Sayuri
Takahashi,Walter Yukihiko
dc.subject.por.fl_str_mv Diabetic retinopathy/surgery
Vitrectomy
Angiogenesis inhibitors/therapeutic use
Triamcinolone/therapeutic use
Visual acuity
topic Diabetic retinopathy/surgery
Vitrectomy
Angiogenesis inhibitors/therapeutic use
Triamcinolone/therapeutic use
Visual acuity
description PURPOSE: To evaluate the effect of preoperative intravitreal bevacizumab (IVB) or triamcinolone (IVT) on the rate of early postvitrectomy hemorrhage in proliferative diabetic retinopathy (PDR). METHODS: Eligible eyes were assigned randomly to 1 of 3 groups: the IVB group received 1.25 mg bevacizumab, the IVT group received 4,0mg triamcinolone and the control group underwent a sham procedure. The primary outcome measure was the incidence of early postvitrectomy hemorrhage. Secondary outcome measures included changes in visual acuity (BCVA) and adverse events. RESULTS: Twenty and seven eyes, 9 in each group were randomized. The incidence of vitreous hemorrhage was lower in the IVB group (p=0.18). Postoperative vitreous hemorrhage at 1 month also was less in the IVB group compared with the control group (p &gt; 0.05). The rate of bleeding immediately after surgery was higher in IVT group with 4 (44.4%) cases. The overall mean visual acuity was 1.72 ± 0.37 logMAR preoperatively and 1.32 ± 0.73 logMAR in 6 months after surgery. Accessing visual acuity by group evidenced that the IVB group had initial mean logMAR VA of 1.87 and 1.57 logMAR VA at the six months (p = 0.84). In IVT group, initial mean VA was 1.75 logMAR and 0.96 logMAR VA at six months (p < 0.001). And in control group, the initial mean VA was 1.85 logMAR and 1.57 logMAR VA at six months (p= 0.34). CONCLUSION: Intravitreal injection of bevacizumab 1 week before vitrectomy seems to reduce the incidence of early postvitrectomy hemorrhage in diabetic patients. There was a better visual acuity outcome in the triamcinolone group.
publishDate 2013
dc.date.none.fl_str_mv 2013-02-01
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0034-72802013000100003
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0034-72802013000100003
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 10.1590/S0034-72802013000100003
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv text/html
dc.publisher.none.fl_str_mv Sociedade Brasileira de Oftalmologia
publisher.none.fl_str_mv Sociedade Brasileira de Oftalmologia
dc.source.none.fl_str_mv Revista Brasileira de Oftalmologia v.72 n.1 2013
reponame:Revista Brasileira de Oftalmologia (Online)
instname:Sociedade Brasileira de Oftalmologia (SBO)
instacron:SBO
instname_str Sociedade Brasileira de Oftalmologia (SBO)
instacron_str SBO
institution SBO
reponame_str Revista Brasileira de Oftalmologia (Online)
collection Revista Brasileira de Oftalmologia (Online)
repository.name.fl_str_mv Revista Brasileira de Oftalmologia (Online) - Sociedade Brasileira de Oftalmologia (SBO)
repository.mail.fl_str_mv sob@sboportal.org.br||rbo@sboportal.org.br
_version_ 1752122336443629568